FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387100811> ?p ?o ?g. }

• W4387100811 abstract "Abstract Background Older adults with heart failure often experience adverse drug events with high doses of heart failure medications. Recognizing whether a patient is on a high or low dose intensity heart failure medication can be helpful for daily practice, since it could potentially guide the physician on which symptoms to look for, whether from overdosing or underdosing. However, the current guideline does not provide sufficient information about the dose intensity below the target dose. Furthermore, the definition of high or low-intensity heart failure medication is unclear, and there is no consensus. Methods To close the knowledge gap, we conducted a scoping review of the current literature to identify the most frequently used definition of high versus low doses of heart failure medications. We searched Pubmed, Embase, CINAHL, and Cochrane Library using comprehensive search terms that can capture the intensity of heart failure medications. Results We reviewed 464 articles, including 144 articles that had information about beta-blockers (BB), 179 articles about angiotensin-converting enzyme inhibitors (ACEi), 75 articles about angiotensin receptor blockers (ARB), 80 articles about diuretics, 37 articles about mineralocorticoid receptor antagonists (MRA), and 33 articles about angiotensin receptor-neprilysin inhibitor (ARNI). For hydralazine with isosorbide dinitrate or ivabradine, we could not identify any eligible articles. We identified 40 medications with most frequently used definitions of dose intensity. Four medications (nadolol, pindolol, cilazapril, and torsemide) did not reach consensus in definitions. Most of the BBs, ACEis, or ARBs used the definition of low being < 50% of the target dose and high being ≥ 50% of the target dose from the guideline. However, for lisinopril and losartan, the most commonly used definitions of high or low were from pivotal clinical trials with a pre-defined definition of high or low. Conclusion Our comprehensive scoping review studies identified the most frequently used definition of dose intensity for 40 medications but could not identify the definitions for 4 medications. The results of the current scoping review will be helpful for clinicians to have awareness whether the currently prescribed dose is considered high - requiring close monitoring of side effects, or low - requiring more aggressive up-titration." @default.
• W4387100811 created "2023-09-28" @default.
• W4387100811 creator A5008079250 @default.
• W4387100811 creator A5031229218 @default.
• W4387100811 creator A5032866121 @default.
• W4387100811 creator A5041491637 @default.
• W4387100811 creator A5046225712 @default.
• W4387100811 creator A5048574696 @default.
• W4387100811 creator A5081327172 @default.
• W4387100811 creator A5086297574 @default.
• W4387100811 date "2023-09-27" @default.
• W4387100811 modified "2023-10-17" @default.
• W4387100811 title "How do we define high and low dose intensity of heart failure medications: a scoping review" @default.
• W4387100811 cites W1984373050 @default.
• W4387100811 cites W1994892923 @default.
• W4387100811 cites W2026091334 @default.
• W4387100811 cites W2062530590 @default.
• W4387100811 cites W2088759164 @default.
• W4387100811 cites W2105138814 @default.
• W4387100811 cites W2119340816 @default.
• W4387100811 cites W2122914905 @default.
• W4387100811 cites W2129711762 @default.
• W4387100811 cites W2142955862 @default.
• W4387100811 cites W2509537460 @default.
• W4387100811 cites W2560438049 @default.
• W4387100811 cites W2609605008 @default.
• W4387100811 cites W2778763254 @default.
• W4387100811 cites W2883756867 @default.
• W4387100811 cites W2891378911 @default.
• W4387100811 cites W2901669506 @default.
• W4387100811 cites W2924113265 @default.
• W4387100811 cites W4225396975 @default.
• W4387100811 cites W4238907867 @default.
• W4387100811 cites W4287577106 @default.
• W4387100811 doi "https://doi.org/10.1186/s12872-023-03514-2" @default.
• W4387100811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37759279" @default.
• W4387100811 hasPublicationYear "2023" @default.
• W4387100811 type Work @default.
• W4387100811 citedByCount "0" @default.
• W4387100811 crossrefType "journal-article" @default.
• W4387100811 hasAuthorship W4387100811A5008079250 @default.
• W4387100811 hasAuthorship W4387100811A5031229218 @default.
• W4387100811 hasAuthorship W4387100811A5032866121 @default.
• W4387100811 hasAuthorship W4387100811A5041491637 @default.
• W4387100811 hasAuthorship W4387100811A5046225712 @default.
• W4387100811 hasAuthorship W4387100811A5048574696 @default.
• W4387100811 hasAuthorship W4387100811A5081327172 @default.
• W4387100811 hasAuthorship W4387100811A5086297574 @default.
• W4387100811 hasBestOaLocation W43871008111 @default.
• W4387100811 hasConcept C126322002 @default.
• W4387100811 hasConcept C164705383 @default.
• W4387100811 hasConcept C177713679 @default.
• W4387100811 hasConcept C27016395 @default.
• W4387100811 hasConcept C2775915353 @default.
• W4387100811 hasConcept C2777386981 @default.
• W4387100811 hasConcept C2777953023 @default.
• W4387100811 hasConcept C2778198053 @default.
• W4387100811 hasConcept C2779167562 @default.
• W4387100811 hasConcept C2779611605 @default.
• W4387100811 hasConcept C2781352967 @default.
• W4387100811 hasConcept C71924100 @default.
• W4387100811 hasConcept C84393581 @default.
• W4387100811 hasConceptScore W4387100811C126322002 @default.
• W4387100811 hasConceptScore W4387100811C164705383 @default.
• W4387100811 hasConceptScore W4387100811C177713679 @default.
• W4387100811 hasConceptScore W4387100811C27016395 @default.
• W4387100811 hasConceptScore W4387100811C2775915353 @default.
• W4387100811 hasConceptScore W4387100811C2777386981 @default.
• W4387100811 hasConceptScore W4387100811C2777953023 @default.
• W4387100811 hasConceptScore W4387100811C2778198053 @default.
• W4387100811 hasConceptScore W4387100811C2779167562 @default.
• W4387100811 hasConceptScore W4387100811C2779611605 @default.
• W4387100811 hasConceptScore W4387100811C2781352967 @default.
• W4387100811 hasConceptScore W4387100811C71924100 @default.
• W4387100811 hasConceptScore W4387100811C84393581 @default.
• W4387100811 hasFunder F4320337337 @default.
• W4387100811 hasIssue "1" @default.
• W4387100811 hasLocation W43871008111 @default.
• W4387100811 hasLocation W43871008112 @default.
• W4387100811 hasOpenAccess W4387100811 @default.
• W4387100811 hasPrimaryLocation W43871008111 @default.
• W4387100811 hasRelatedWork W1605334996 @default.
• W4387100811 hasRelatedWork W1979704758 @default.
• W4387100811 hasRelatedWork W2052242574 @default.
• W4387100811 hasRelatedWork W2058708816 @default.
• W4387100811 hasRelatedWork W2103648677 @default.
• W4387100811 hasRelatedWork W2360752628 @default.
• W4387100811 hasRelatedWork W2795216625 @default.
• W4387100811 hasRelatedWork W2887124172 @default.
• W4387100811 hasRelatedWork W4387100811 @default.
• W4387100811 hasRelatedWork W2488445580 @default.
• W4387100811 hasVolume "23" @default.
• W4387100811 isParatext "false" @default.
• W4387100811 isRetracted "false" @default.
• W4387100811 workType "article" @default.